Research and Development Expenses Breakdown: United Therapeutics Corporation vs Galapagos NV

Biotech R&D: United Therapeutics vs. Galapagos NV

__timestampGalapagos NVUnited Therapeutics Corporation
Wednesday, January 1, 2014111110000242549000
Thursday, January 1, 2015129714000245098000
Friday, January 1, 2016139574000147600000
Sunday, January 1, 2017218502000264600000
Monday, January 1, 2018322876000357900000
Tuesday, January 1, 20194273200001182600000
Wednesday, January 1, 2020523667000357700000
Friday, January 1, 2021491707000540100000
Saturday, January 1, 2022515083000322900000
Sunday, January 1, 2023241294000408000000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending Trends in Biotech Giants

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and Galapagos NV have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, United Therapeutics consistently outpaced Galapagos NV, with an average annual R&D expenditure of approximately 30% higher. Notably, in 2019, United Therapeutics' R&D spending peaked, reaching nearly three times its 2016 levels, highlighting a strategic push in innovation. Meanwhile, Galapagos NV showed a steady increase in R&D spending, peaking in 2020, before a notable decline in 2023. This fluctuation suggests a strategic pivot or a response to external market pressures. As these companies navigate the competitive biotech landscape, their R&D investments will continue to shape their future breakthroughs and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025